نتایج جستجو برای: nph insulin

تعداد نتایج: 183665  

Journal: :Diabetes 2000
M Lepore S Pampanelli C Fanelli F Porcellati L Bartocci A Di Vincenzo C Cordoni E Costa P Brunetti G B Bolli

To compare the pharmacokinetics/dynamics of the long-acting insulin analog glargine with NPH, ultralente, and continuous subcutaneous (SC) infusion of insulin lispro (continuous subcutaneous insulin infusion [CSII]), 20 C-peptide-negative type 1 diabetic patients were studied on four occasions during an isoglycemic 24-h clamp. Patients received SC injection of either 0.3 U/kg glargine or NPH in...

2016
Min Liu Zhiguang Zhou Jinhua Yan Pin Li Wenhui Song Junfen Fu Xiaobo Chen Weigang Zhao Li Xi Xiaoping Luo Liang Sha Xueyuan Deng Chunxiu Gong

BACKGROUND We aimed to describe the safety and efficacy of insulin glargine in Chinese paediatric patients with type 1 diabetes mellitus (T1DM). Neutral protamine Hagedorn (NPH) insulin was the reference therapy. METHODS This open-label, randomised, Phase III study was conducted at 10 sites in China. Children aged ≥6 to <18 years with T1DM were randomised (2:1) to insulin glargine or NPH insu...

Journal: :Diabetes care 2003
Nuala P Murphy Suzanne M Keane Ken K Ong Martha Ford-Adams Julie A Edge Carlo L Acerini David B Dunger

OBJECTIVE To compare blood glucose control and incidence of nocturnal hypoglycemia in adolescents with type 1 diabetes on multiple injection regimens managed with either an insulin analog combination or NPH insulin plus regular human insulin. RESEARCH DESIGN AND METHODS In a randomized cross-over study, 28 adolescents with type 1 diabetes on multiple injection therapy received either insulin ...

2014
Larissa W. van Golen Dick J. Veltman Richard G. IJzerman Jan Berend Deijen Annemieke C. Heijboer Frederik Barkhof Madeleine L. Drent Michaela Diamant

UNLABELLED Studies in rodents have demonstrated that insulin in the central nervous system induces satiety. In humans, these effects are less well established. Insulin detemir is a basal insulin analog that causes less weight gain than other basal insulin formulations, including the current standard intermediate-long acting Neutral Protamine Hagedorn (NPH) insulin. Due to its structural modific...

Journal: :Diabetes care 2003
Paolo Rossetti Simone Pampanelli Carmine Fanelli Francesca Porcellati Emanuela Costa Elisabetta Torlone Luciano Scionti Geremia B Bolli

OBJECTIVE To establish differences in blood glucose between different regimens of optimized basal insulin substitution in type 1 diabetic patients given lispro insulin at meals, i.e., NPH injected four times a day versus glargine insulin once daily at dinner or at bedtime. RESEARCH DESIGN AND METHODS A total of 51 patients with type 1 diabetes on intensive therapy (NPH four times/day and lisp...

Journal: :Diabetes care 2005
Julio Rosenstock George Dailey Massimo Massi-Benedetti Andreas Fritsche Zhengning Lin Alan Salzman

OBJECTIVE Insulin glargine (LANTUS) is a once-daily basal insulin analog with a smooth 24-h time-action profile that provides effective glycemic control with reduced hypoglycemia risk (particularly nocturnal) compared with NPH insulin in patients with type 2 diabetes. A recent "treat-to-target" study has shown that more patients on insulin glargine reached HbA(1c) levels < or =7.0% without conf...

Journal: :Diabetes care 2006
Kjeld Hermansen Melanie Davies Taudeusz Derezinski Gabrielle Martinez Ravn Per Clauson Philip Home

OBJECTIVE To assess efficacy and tolerability of insulin detemir or NPH insulin added to oral therapy for type 2 diabetes in a treat-to-target titration protocol. RESEARCH DESIGN AND METHODS Individuals (n = 476) with HbA(1c) (A1C) 7.5-10.0% were randomized to addition of twice-daily insulin detemir or NPH insulin in a parallel-group, multicenter trial. Over 24 weeks, insulin doses were titra...

2013
Aimee J. Varewijck Hannele Yki-Järvinen Ronald Schmidt Norbert Tennagels Joseph A.M.J.L. Janssen

We investigated 1) the ability of purified glargine (GLA), metabolites 1 (M1) and 2 (M2), IGF-I, and NPH insulin to activate the insulin receptor (IR)-A and IR-B and IGF-I receptor (IGF-IR) in vitro; 2) plasma concentrations of GLA, M1, and M2 during long-term insulin therapy in type 2 diabetic patients; and 3) IR-A and IR-B activation in vitro induced by serum from patients treated with GLA or...

2017
Åsa Ericsson Adam Lundqvist

BACKGROUND Patients with uncontrolled type 2 diabetes mellitus (T2DM) are a priority group for intensified therapy without weight gain and with low risk of hypoglycaemia. OBJECTIVE This study evaluates the cost effectiveness of insulin degludec plus liraglutide (IDegLira, Xultophy®) compared with six potential intensification treatment options for patients with T2DM that is uncontrolled with ...

Journal: :Polskie Archiwum Medycyny Wewnetrznej 2011
Agnieszka Szypowska Dominik Golicki Lidia Groele Ewa Pańkowska

INTRODUCTION Although numerous studies showed an improvement in glycemic control in type 1 diabetic patients treated with long-acting insulin analogue detemir compared with Neutral Protamine Hagedorn (NPH) insulin, the beneficial effects of insulin detemir has not been confirmed by all investigators. OBJECTIVES The aim of the study was to compare the effect of treatment with detemir insulin v...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید